pharmaphorum4d
UCB looks ahead to next phase
and the slow post-patent decline of epilepsy drug Keppra. UCB now has three core brands: Cimzia, for Crohn's disease and rheumatoid arthritis (RA), epilepsy treatment Vimpat and Neupro for ...
pharmaphorum10d
Failed trial puts future of UCB’s epilepsy drug padsevonil in doubt
Shares in UCB slid this morning after the Belgian company announced its refractory epilepsy drug candidate padsevonil had failed a phase 2b trial. The ARISE trial of padsevonil did not reach ...
Hosted on MSN2mon
CBC acquires UCB’s neurology and allergy business in China
The deal encompasses UCB's Zhuhai manufacturing site and its brands Xyzal, Keppra, Zyrtec, Vimpat and Neupro. They are set to be the cornerstone assets for CBC as it develops an integrated central ...
Monthly Prescribing Reference3y
Keppra Injection
Enroll pregnant patients exposed to levetiracetam in the North American Antiepileptic Drug pregnancy registry (888) 233-2334 or the UCB AED Pregnancy Registry (888) 537-7734.
Monthly Prescribing Reference3y
Keppra Xr
Enroll pregnant patients exposed to levetiracetam in the North American Antiepileptic Drug pregnancy registry (888) 233-2334 or the UCB AED Pregnancy Registry (888) 537-7734.
UCB SA (0NZT) Receives a Hold from Kepler Capital
Kepler Capital analyst David Evans maintained a Hold rating on UCB SA (0NZT – Research Report) on January 31 and set a price target of ...